Reimbursed Care Access in Cocos (Keeling) Islands

Australia rescheduled psilocybin to Schedule 8 with a tightly controlled medical access pathway effective 1 July 2023: psychiatrists may prescribe psilocybin for treatment‑resistant depression only if they are approved as an Authorised Prescriber under the TGA scheme and meet the clinical/administrative safeguards set by the TGA. Access requires compliance with both Commonwealth import/manufacture controls and state/territory controlled‑drug rules; products containing psilocybin remain generally unlisted on the ARTG and are treated as unapproved therapeutic goods unless a product becomes ARTG‑listed. Practical access therefore depends on (a) an authorised psychiatrist; (b) obtaining any required Office of Drug Control / TGA permits for import or manufacture; and (c) satisfying state/territory requirements where Western Australian laws may apply in the Cocos (Keeling) Islands as delegated by the Commonwealth. Costs: there is currently no broad PBS reimbursement pathway for TGA Authorised Prescriber access to psilocybin (treatment will largely be paid out‑of‑pocket or by private insurer arrangements if available), and the TGA has warned rollout and supply will be slow due to training, supply and strict safeguards. For implementation details see the TGA guidance and the clinical/regulatory analyses published since rescheduling. # #.

MDMA was reclassified in Australia so that, from 1 July 2023, suitably authorised psychiatrists may prescribe MDMA for post‑traumatic stress disorder (PTSD) under the TGA Authorised Prescriber framework and subject to strict Commonwealth and state/territory import/manufacture/supply controls. Like psilocybin, MDMA products are tightly controlled, are not broadly ARTG‑listed as consumer medicines, and require supply/import authorisations (including Office of Drug Control licences as appropriate). There is no general PBS reimbursement entitlement for MDMA‑assisted therapy under the TGA Authorised Prescriber pathway: patients should expect the cost of product, multi‑session therapy and facility costs to be borne privately unless a specific ARTG product is later listed on the PBS or private insurers develop explicit cover. State and territory regulators have been instructed to implement additional safeguards and some jurisdictions have interpreted safeguards more conservatively in practice—clinician training, approved facility arrangements and inpatient/outpatient settings are important implementation details that vary by jurisdiction. # #.

Esketamine nasal spray (marketed as SPRAVATO) is registered by the TGA for treatment‑resistant major depressive disorder and was added to the Australian Register of Therapeutic Goods (ARTG) in March 2021; it was subsequently listed on the Pharmaceutical Benefits Scheme (PBS) with an effective subsidised availability process introduced in 2025–2026, making it a reimbursed option for eligible patients meeting the PBS clinical criteria. The TGA ARTG product record confirms registration (SPRAVATO ARTG 311827, registration date 9 March 2021). #. The federal PBS listing and implementation guidance (announced for implementation in 2025) set out eligibility criteria consistent with treatment‑resistant depression (patients who have failed at least two adequate antidepressant trials) and require administration in supervised settings because of monitoring and safety obligations; state health authorities (and professional registration requirements) control which clinicians may prescribe and the arrangements for supply/administration (e.g., Ahpra‑registered psychiatrists and accredited clinics). PBS listing materially reduces patient drug cost (PBS co‑payment rates apply), but additional clinical administration, monitoring and facility fees may remain out‑of‑pocket. For PBS listing and clinical implementation summaries see the PBS / RANZCP / state health communications. # # #.

Ketamine (often used as intravenous or intramuscular racemic ketamine) is widely used in Australia in clinical settings (anaesthesia, emergency medicine) and is also used off‑label in psychiatric practice for treatment‑resistant depression and suicidal crises. Off‑label psychiatric use requires clinical governance: in many jurisdictions prescribing and supply for TRD must be managed by Ahpra‑registered psychiatrists and may require approvals depending on state‑level S8 controls; ketamine formulations used in psychiatry are generally not PBS‑subsidised for off‑label psychiatric indications, so treatment is usually private‑pay or funded via private health insurance where allowed. States have issued implementation notes and approval processes (for example NSW has specific application/approval pathways for injectable ketamine in TRD). Ketamine for anaesthesia or other approved indications remains standard medical practice. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and DMT‑containing preparations such as ayahuasca) is a prohibited/controlled substance under Australian state/territory laws and the Poisons Standard, and possession, manufacture or supply is criminalised except where special research or import/manufacture permits are issued. See commentary on ayahuasca/DMT criminalisation and penalties across Australian jurisdictions. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT and related tryptamines are treated as prohibited substances under Australian scheduling and state/territory controlled‑drugs laws; access is only possible via special research authorisations. (See Poisons Standard / state controlled‑substances frameworks.) #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Historical and jurisdictional sources vary in precise scheduling language, but in practice ibogaine is not an accepted, reimbursed medical therapy in Australia and legal clinical access is extremely limited (research‑only or requires specific TGA/ODC authorisations); many clinical‑use providers operate outside Australia. Patients seeking ibogaine typically must travel to other jurisdictions where national/regulatory frameworks permit medical use. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT, their import, possession and use are illegal under Australian controlled‑drugs and poisons laws except where a specific research or import permit is granted. Some state laws impose criminal penalties for possession/supply of DMT‑containing preparations. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled under Australian scheduling and state legislation; medical or religious exemptions are not part of routine clinical practice and access is limited to authorised research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines (including 2C‑class compounds) are controlled under Australian law and subject to criminal penalties; there is no authorised therapeutic framework for 2C‑X compounds outside tightly regulated research. #.